Design Therapeutics to Participate in the 2025 Cantor Global Healthcare Conference
Design Therapeutics (NASDAQ:DSGN), a clinical-stage biotech company focused on developing treatments for degenerative genetic diseases, has announced its participation in the upcoming 2025 Cantor Global Healthcare Conference. The company's management will engage in a fireside chat on September 4, 2025, at 10:55 a.m. ET in New York.
Investors can access the presentation through a live webcast available on the company's website, which will remain archived for at least 30 days after the event.
Design Therapeutics (NASDAQ:DSGN), biotech in fase clinica specializzata nello sviluppo di terapie per malattie genetiche degenerative, parteciperà al 2025 Cantor Global Healthcare Conference. Il management terrà un fireside chat il 4 settembre 2025 alle 10:55 ET a New York.
Gli investitori potranno seguire la presentazione tramite webcast in diretta sul sito della società; la registrazione resterà disponibile in archivio per almeno 30 giorni dopo l'evento.
Design Therapeutics (NASDAQ:DSGN), una biotecnológica en fase clínica dedicada a desarrollar tratamientos para enfermedades genéticas degenerativas, ha anunciado su participación en la 2025 Cantor Global Healthcare Conference. La dirección de la compañía participará en un fireside chat el 4 de septiembre de 2025 a las 10:55 a.m. ET en Nueva York.
Los inversores podrán acceder a la presentación mediante un webcast en vivo en la web de la compañía; la grabación permanecerá archivada al menos 30 días tras el evento.
Design Therapeutics (NASDAQ:DSGN)는 퇴행성 유전 질환 치료제 개발에 주력하는 임상 단계 바이오텍으로, 다가오는 2025 Cantor Global Healthcare Conference에 참가한다고 발표했습니다. 회사 경영진은 2025년 9월 4일 오전 10:55(동부시간) 뉴욕에서 파이어사이드 채팅에 참여할 예정입니다.
투자자들은 회사 웹사이트에서 제공되는 라이브 웹캐스트로 발표를 시청할 수 있으며, 행사는 종료 후 최소 30일간 아카이브로 제공됩니다.
Design Therapeutics (NASDAQ:DSGN), une société biotechnologique en phase clinique dédiée au développement de traitements pour des maladies génétiques dégénératives, a annoncé sa participation à la 2025 Cantor Global Healthcare Conference. La direction tiendra un fireside chat le 4 septembre 2025 à 10h55 ET à New York.
Les investisseurs pourront suivre la présentation via un webcast en direct sur le site de la société ; l'enregistrement restera archivé pendant au moins 30 jours après l'événement.
Design Therapeutics (NASDAQ:DSGN), ein klinisch fortgeschrittenes Biotech-Unternehmen, das Behandlungen für degenerative genetische Erkrankungen entwickelt, kündigt seine Teilnahme an der 2025 Cantor Global Healthcare Conference an. Das Management wird am 4. September 2025 um 10:55 Uhr ET in New York in einem Fireside-Chat auftreten.
Investoren können die Präsentation über einen Live-Webcast auf der Unternehmenswebsite verfolgen; die Aufzeichnung wird mindestens 30 Tage nach der Veranstaltung archiviert bleiben.
- None.
- None.
CARLSBAD, Calif., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Design Therapeutics, Inc. (Nasdaq: DSGN), a clinical-stage biotechnology company developing treatments for serious degenerative genetic diseases, today announced that management will participate in a fireside chat at the 2025 Cantor Global Healthcare Conference on Thursday, September 4, 2025, at 10:55 a.m. ET in New York.
A live webcast of the fireside chat will be available here and in the investors section of the company’s website at www.designtx.com. The webcast will be archived for at least 30 days following the presentation.
About Design Therapeutics
Design Therapeutics is a clinical-stage biotechnology company developing a new class of therapies based on its platform of GeneTAC® gene targeted chimera small molecules. The company’s GeneTAC® molecules are designed to either dial up or dial down the expression of a specific disease-causing gene to address the underlying cause of disease. In addition to its clinical-stage GeneTAC® programs, DT-216P2, in development for patients with Friedreich ataxia, and DT-168, for Fuchs endothelial corneal dystrophy, the company is advancing programs in myotonic dystrophy type-1 and Huntington’s disease. Discovery efforts are underway for multiple genomic medicines. For more information, please visit designtx.com.
Contact:
Renee Leck
THRUST Strategic Communications
renee@thrustsc.com
FAQ
When is Design Therapeutics (DSGN) presenting at the 2025 Cantor Global Healthcare Conference?
How can investors access Design Therapeutics' (DSGN) presentation at the Cantor Conference?
How long will Design Therapeutics' (DSGN) Cantor Conference presentation be available online?
What type of company is Design Therapeutics (DSGN)?
